Clinical Trial Update: Irinotecan and Bevacizumab for Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of irinotecan and bevacizumab in recurrent ovarian cancer (including fallopian tube cancer and primary peritoneal car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Carcinoma

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Irinotecan (Camptosar) (Irinotecan)

Snippet

Sponsor: NYU Langone Health | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-10-19